What is the role and efficacy of Vebreltinib?

Vebreltinib (vebreltinib) is a domestic targeted therapy drug that has attracted much attention in recent years. It is a selective MET tyrosine kinase inhibitor. With in-depth research on the molecular mechanisms of tumors, scientists have discovered that abnormal activation of the MET gene is closely related to the occurrence and development of non-small cell lung cancer and some central nervous system tumors. Brixitinib is an innovative drug designed to target this pathway. Its main mechanism of action is to highly selectively inhibit MET receptor tyrosine kinase activity, thereby blocking tumor cell signaling pathways and inhibiting cell proliferation, invasion and metastasis. This mechanism allows bricitinib to exhibit more precise therapeutic potential in specific genetic backgrounds.

In clinical application, boricitinib is mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer associated withMET exon 14 skipping. For this type of patients, traditional chemotherapy or immunotherapy often has limited effects, while bricitinib improves the effectiveness and tolerability of treatment by accurately identifying molecular targets. At the same time, the drug has also shown potential efficacy in some patients with brain glioma, especially cases of astrocytoma or glioblastoma with the PTPRZ1-MET fusion gene. Due to limited treatment options for brain glioma, the emergence of boricitinib has brought new hope to some patients

The efficacy of bricitinib is not only reflected in its precise target and clear mechanism, but also in its good oral convenience. Patients take it through enteric-coated capsules, which avoids the inconvenience of intravenous injection and improves compliance. According to existing overseas and domestic reports, the drug has a positive effect in controlling tumor progression, and some patients can obtain a longer disease remission period. It is worth emphasizing that although boricitinib shows good application prospects, its efficacy is still closely related to the individual patient's genetic status, disease progression and combined treatment regimen, so it must be used under the guidance of a doctor.

Reference materials:https://www.asymbio.com.cn/